PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.
Valentina GuarneriMaria Vittoria DieciGiancarlo BisagniAlba A BrandesAntonio FrassoldatiLuigi CavannaAntonino MusolinoFrancesco GiottaAnita RimantiOrnella GarroneElena BertoneKatia CagossiOriana NanniEnrico OrvietoGaia GriguoloMatteo CurtarelloLoredana UrsoLaia ParéNuria ChicRoberto D'AmicoAleix PratPierFranco ContePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
PIK3CA mutation showed no prognostic impact in the ShortHER trial. Within the HER2-enriched molecular subtype, patients with PIK3CA mutated tumors showed better DFS versus PIK3CA wild-type, which may be partly explained by upregulation of immune-related genes.